Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free KPRX Stock Alerts

Kiora Pharmaceuticals (KPRX) Competitors

Kiora Pharmaceuticals logo
$2.51 -0.03 (-1.18%)
Closing price 04:00 PM Eastern
Extended Trading
$2.28 -0.23 (-9.16%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

KPRX vs. ALGS, ATNM, TAOX, ADXS, and RNTX

Should you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Aligos Therapeutics (ALGS), Actinium Pharmaceuticals (ATNM), Synaptogenix (TAOX), Ayala Pharmaceuticals (ADXS), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry.

How does Kiora Pharmaceuticals compare to Aligos Therapeutics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Kiora Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 298.41%. Aligos Therapeutics has a consensus target price of $41.50, suggesting a potential upside of 553.54%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Kiora Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiora Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Kiora Pharmaceuticals has higher revenue and earnings than Aligos Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiora Pharmaceuticals$16.02M0.69-$10.84M-$2.65N/A
Aligos Therapeutics$2.19M17.95-$24.19M-$8.59N/A

In the previous week, Kiora Pharmaceuticals and Kiora Pharmaceuticals both had 1 articles in the media. Aligos Therapeutics' average media sentiment score of 0.27 beat Kiora Pharmaceuticals' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kiora Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aligos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Kiora Pharmaceuticals has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,106.72%. Aligos Therapeutics' return on equity of -28.16% beat Kiora Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Kiora PharmaceuticalsN/A -51.37% -36.09%
Aligos Therapeutics -1,106.72%-28.16%-20.01%

Kiora Pharmaceuticals has a beta of -0.48, suggesting that its share price is 148% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500.

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Aligos Therapeutics beats Kiora Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Actinium Pharmaceuticals presently has a consensus target price of $4.50, suggesting a potential upside of 257.14%. Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 298.41%. Given Kiora Pharmaceuticals' higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Actinium Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actinium Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Kiora Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Kiora Pharmaceuticals has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium Pharmaceuticals$90K439.25-$48.82M-$1.08N/A
Kiora Pharmaceuticals$16.02M0.69-$10.84M-$2.65N/A

In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 1 mentions for Kiora Pharmaceuticals and 0 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Actinium Pharmaceuticals Neutral
Kiora Pharmaceuticals Neutral

Kiora Pharmaceuticals' return on equity of -51.37% beat Actinium Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Actinium PharmaceuticalsN/A -100.85% -47.89%
Kiora Pharmaceuticals N/A -51.37%-36.09%

Actinium Pharmaceuticals has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.48, suggesting that its stock price is 148% less volatile than the S&P 500.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Kiora Pharmaceuticals beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Kiora Pharmaceuticals has higher revenue and earnings than Synaptogenix. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synaptogenix$300K140.69-$28.74M-$17.14N/A
Kiora Pharmaceuticals$16.02M0.69-$10.84M-$2.65N/A

Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 298.41%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Synaptogenix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synaptogenix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Kiora Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Synaptogenix. MarketBeat recorded 1 mentions for Kiora Pharmaceuticals and 0 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Synaptogenix Neutral
Kiora Pharmaceuticals Neutral

Kiora Pharmaceuticals' return on equity of -51.37% beat Synaptogenix's return on equity.

Company Net Margins Return on Equity Return on Assets
SynaptogenixN/A -193.08% -144.93%
Kiora Pharmaceuticals N/A -51.37%-36.09%

Synaptogenix has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.48, suggesting that its share price is 148% less volatile than the S&P 500.

Summary

Kiora Pharmaceuticals beats Synaptogenix on 10 of the 13 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 1 mentions for Kiora Pharmaceuticals and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Ayala Pharmaceuticals Neutral
Kiora Pharmaceuticals Neutral

Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 298.41%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Ayala Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ayala Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Kiora Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Ayala Pharmaceuticals' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ayala PharmaceuticalsN/A N/A N/A
Kiora Pharmaceuticals N/A -51.37%-36.09%

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.48, suggesting that its share price is 148% less volatile than the S&P 500.

Kiora Pharmaceuticals has higher revenue and earnings than Ayala Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayala Pharmaceuticals$3.24M11.05-$48.07M-$5.02N/A
Kiora Pharmaceuticals$16.02M0.69-$10.84M-$2.65N/A

Summary

Kiora Pharmaceuticals beats Ayala Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Rein Therapeutics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, Rein Therapeutics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 2 mentions for Rein Therapeutics and 1 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled Rein Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kiora Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rein Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Kiora Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 298.41%. Rein Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 684.31%. Given Rein Therapeutics' higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than Kiora Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiora Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Rein Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Kiora Pharmaceuticals' return on equity of -51.37% beat Rein Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kiora PharmaceuticalsN/A -51.37% -36.09%
Rein Therapeutics N/A -510.35%-56.38%

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Rein Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kiora Pharmaceuticals has a beta of -0.48, suggesting that its share price is 148% less volatile than the S&P 500. Comparatively, Rein Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Kiora Pharmaceuticals has higher revenue and earnings than Rein Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiora Pharmaceuticals$16.02M0.69-$10.84M-$2.65N/A
Rein TherapeuticsN/AN/A-$49.87M-$1.96N/A

Summary

Rein Therapeutics beats Kiora Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Get Kiora Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KPRX vs. The Competition

Export
MetricKiora PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$11.26M$3.10B$6.24B$11.86B
Dividend YieldN/A1.91%2.73%5.21%
P/E RatioN/A18.3729.0428.48
Price / Sales0.69272.31477.1060.43
Price / CashN/A50.4327.6236.52
Price / Book0.574.339.676.67
Net Income-$10.84M$72.19M$3.55B$332.64M
7 Day Performance7.73%2.03%1.70%2.01%
1 Month Performance29.38%6.42%5.62%9.19%
1 Year Performance-23.94%37.74%34.42%39.59%

Kiora Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KPRX
Kiora Pharmaceuticals
1.6868 of 5 stars		$2.51
-1.2%		$10.00
+298.4%		N/A$11.26M$16.02MN/A10
ALGS
Aligos Therapeutics
3.6895 of 5 stars		$5.97
-5.1%		$41.50
+595.1%		N/A$36.94M$2.19MN/A90
ATNM
Actinium Pharmaceuticals
2.1544 of 5 stars		$1.17
-1.7%		$4.50
+284.6%		N/A$36.71M$90KN/A30
TAOX
Synaptogenix
N/A$4.83
-4.4%		N/AN/A$36.08M$300KN/A4
ADXS
Ayala Pharmaceuticals
N/A$0.60
flat		N/AN/A$35.79M$3.24MN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KPRX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel